Search

Your search keyword '"F. Trinkmann"' showing total 121 results
Start Over Author "F. Trinkmann"
121 results on '"F. Trinkmann"'

1. Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort

Author

N. Frantzi, X. P. Nguyen, C. Herr, P. Alter, S. Söhler, D. Soriano, H. Watz, B. Waschki, F. Trinkmann, M. Eichenlaub, F. C. Trudzinski, J. D. Michels-Zetsche, A. Omlor, F. Seiler, I. Moneke, F. Biertz, G. Rohde, D. Stolz, T. Welte, H. U. Kauczor, K. Kahnert, R. A. Jörres, C. F. Vogelmeier, R. Bals, S. Fähndrich, and on behalf of the German COSYCONET Cohort

Subjects
Statins, COPD, Exacerbations, Cardiovascular comorbidities, Diseases of the respiratory system, RC705-779
Abstract

Abstract Background The evidence regarding effects of statins on exacerbation risk in COPD remains controversial. Previous studies often excluded patients with cardiovascular comorbidities despite their high prevalence in COPD and role for exacerbations. Based on the cardioprotective properties of statins, we hypothesised that statins may reduce the risk of exacerbations especially in patients with cardiovascular comorbidities. Methods One thousand eight hundred eighty seven patients of the German COPD cohort COSYCONET (COPD and Systemic Consequences Comorbidities Network) of GOLD grades 1–4 (37.8% female, mean age 64.78 ± 8.3) were examined at baseline and over a period of 4.5 years for the occurrence of at least one exacerbation or severe exacerbation per year in cross-sectional and longitudinal analyses adjusted for age, gender, BMI, GOLD grade and pack-years. Due to their collinearity, various cardiovascular diseases were tested in separate analyses, whereby the potential effect of statins in the presence of a specific comorbidity was tested as interaction between statins and comorbidity. We also identified patients who never took statins, always took statins, or initiated statin intake during the follow-up. Results One thousand three hundred six patients never took statins, 31.6% were statin user, and 12.9% initiated statins during the follow-up. Most cardiovascular diseases were significantly (p

Published
2024
Full Text
View/download PDF

20. Multiple Breath Washout Using Sulfur Hexafluoride - Lung Clearance Index (LCI) Reference Values and Influence of Anthropometric Parameters

Author

J Gawlitza, Ibrahim Akin, F Trinkmann, F.J. Herth, M. Borggrefe, K Roth, J Schäfer, M. Maros, J Saur, T. Ganslandt, and A. Hermanns

Subjects
Sulfur hexafluoride, Anthropometric parameters, chemistry.chemical_compound, chemistry, business.industry, Reference values, Medicine, Lung Clearance Index, business, Nuclear medicine, MULTIPLE BREATH WASHOUT
Published
2020
Full Text
View/download PDF

26. Characterization of Lung Function in Coronary Heart Disease and Chronic Obstructive Pulmonary Disease - Going Beyond Spirometry

Author

T. Sieburg, J Gawlitza, Ibrahim Akin, JD Michels, M. Borggrefe, C Doesch, Ksenija Stach, J. Schaefer, and F Trinkmann

Subjects
Spirometry, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Internal medicine, Cardiology, Medicine, Pulmonary disease, business, Coronary heart disease, Lung function
Published
2019
Full Text
View/download PDF

33. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study

Author

Tobias Boch, Mark Reinwald, Patrick Meybohm, Wolf-K. Hofmann, S. Britsch, F. Trinkmann, Peter Schellongowski, Dieter Buchheidt, Birgit Spiess, Julia D. Michels, Peter-Michael Rath, Tobias Liebregts, C. Jabbour, and Joerg Steinmann

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, beta-Glucans, Critical Illness, 030106 microbiology, Medizin, Pilot Projects, Critical Care and Intensive Care Medicine, Polymerase Chain Reaction, Gastroenterology, law.invention, Mannans, Young Adult, 03 medical and health sciences, Galactomannan, chemistry.chemical_compound, 0302 clinical medicine, law, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Polymerase chain reaction, Aged, Aged, 80 and over, Invasive Pulmonary Aspergillosis, medicine.diagnostic_test, biology, Diagnostic Tests, Routine, business.industry, Galactose, Middle Aged, Intensive care unit, respiratory tract diseases, Clinical trial, Aspergillus, Bronchoalveolar lavage, 1,3-Beta-glucan synthase, chemistry, biology.protein, business, Bronchoalveolar Lavage Fluid, Nested polymerase chain reaction
Abstract

Invasive pulmonary aspergillosis (IPA) is an emerging and life-threatening infectious disease in patients admitted to the intensive care unit (ICU). Most diagnostic studies are conducted in hematological patients and results cannot readily be transferred to ICU patients lacking classical host factors. In a multicenter, prospective clinical trial including 44 ICU patients, hematological (n = 14) and non-hematological patients (n = 30), concurrent serum and bronchoalveolar lavage (BAL) samples were analyzed by conventional culture, galactomannan (GM), 1-3-beta-D-glucan (BDG) as well as an Aspergillus specific nested polymerase chain reaction (PCR). Nine patients (20%) had putative IPA according to AspICU classification. GM and PCR showed superior performance in BAL with sensitivity/specificity of 56%/94% and 44%/94% compared to 33%/97% and 11%/94% in serum. Despite better sensitivity of 89%, BDG showed poor specificity of only 31% (BAL) and 26% (serum). Combination of GM and PCR (BAL) with BDG (serum) resulted in 100% sensitivity, but also reduced specificity to 23%. Whereas mean GM levels were significantly higher in hematological patients BDG and PCR did not differ between hematological and non-hematological patients. Under present clinical conditions test combinations integrating both BAL and blood samples are advantageous. BDG might best serve as possible indicator for ruling out IPA. Trial registration ClinicalTrials.gov Identifier: NCT01695499 . First posted: September 28, 2012, last update posted: May 8, 2017.

Published
2018

50. Eosinopenia as Predictor of Disease Severity in Patients With Community-Acquired Pneumonia: An Observational Study.

Author

Weckler BC, Pott H, Race A, Jugkaeo N, Karki K, Ringshandl S, Seidemann C, Schöndorf I, Renz H, Fähndrich S, Jung AL, Bertrams W, Makoudjou A, Zöller D, Finotto S, Schild S, Seuchter SA, Rohde G, Trinkmann F, Greulich T, Vogelmeier CF, and Schmeck B

Abstract

Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: B. C. W. reports one unpaid participation in an Advisory Board with AstraZeneca. A. L. J. reports research grants from the Behring Röntgen Foundation. G. R. reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis, and Pfizer for consultancy during advisory board meetings and personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer, and Vertex for lectures including service on speakers’ bureaus. F. T. reports consulting fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Fisher & Paykel, GlaxoSmithKline, Janssen-Cilag, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis, and support for attending meetings or travel from AstraZeneca, Actelion, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Mundipharma, Novartis, Pfizer, TEVA. T. G. reports Grant from Grifols to institution for AATD laboratory, consulting fees from AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Novartis, Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Takeda, support for attending meetings or travel from AstraZeneca, Berlin-Chemie, Chiesi, CSL-Behring, Grifols, GSK, Novartis, participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Novartis, Takeda, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as scientific Advisor for Alpha-1-Deutschland. C. F. V. reports grants or contracts from German Ministery of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols, Novartis, consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Nuvaira, Sanofi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Roche, Sanofi. Bernd Schmeck reports Grants or contracts from CSL-Behring. None declared (H. P., A. R., N. J., K. K., S. R., C. S., I. S., H. R., S. Fähndrich., W. B., A. M., D. Z., S. Finotto., S. S., S. A. S., B. S.).

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results